Yong Yu - Aug 18, 2023 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Sean Ryder, Attorney-in-Fact
Stock symbol
GNLX
Transactions as of
Aug 18, 2023
Transactions value $
-$77,478
Form type
4
Date filed
8/22/2023, 05:14 PM
Previous filing
May 2, 2023
Next filing
Aug 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Sale -$77.5K -3.27K -2.05% $23.73 156K Aug 18, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.
F2 The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.